New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations

References

• Benhamou CL, Chamot AM, Kahn MF. Synovitis-acne-pustulosis hyperostosis-osteomyelitis syndrome (SAPHO). A new syndrome among the spondyloarthropathies? Clin Exp Rheumatol. 1988;6(2):109–112.
   PubMed Web of Science ®Google Scholar
• Hayem G. [SAPHO syndrome]. Rev Prat. 2004;54(15):1635–1636. Swedish.
   PubMedGoogle Scholar
• Hayem G, Bouchaud-Chabot A, Benali K, et al. SAPHO syndrome: a long-term follow-up study of 120 cases. Semin Arthritis Rheum. 1999;29(3):159–171. doi:10.1016/S0049-0172(99)80027-4
   PubMed Web of Science ®Google Scholar
• Hayama K, Inadomi T, Fujisawa D, Terui T. A pilot study of medium-dose cyclosporine for the treatment of palmoplantar pustulosis complicated with pustulotic arthro-osteitis. Eur J Dermatol. 2010;20(6):758–762. doi:10.1684/ejd.2010.1109
   PubMed Web of Science ®Google Scholar
• Rozin AP. SAPHO syndrome: is a range of pathogen-associated rheumatic diseases extended? Arthritis Res Ther. 2009;11(6):131. doi:10.1186/ar2837
   PubMed Web of Science ®Google Scholar
• Golla A, Jansson A, Ramser J, et al. Chronic recurrent multifocal osteomyelitis (CRMO): evidence for a susceptibility gene located on chromosome 18q21.3-18q22. Eur J Hum Genet. 2002;10(3):217–221. doi:10.1038/sj.ejhg.5200789
   PubMed Web of Science ®Google Scholar
• Hurtado-Nedelec M, Chollet-Martin S, Nicaise-Roland P, et al. Characterization of the immune response in the synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome. Rheumatology. 2008;47(8):1160–1167. doi:10.1093/rheumatology/ken185
   PubMed Web of Science ®Google Scholar
• Berthelot JM, Corvec S, Hayem G. SAPHO, autophagy, IL-1, FoxO1, and Propionibacterium (Cutibacterium) acnes. Joint Bone Spine. 2018;85(2):171–176. doi:10.1016/j.jbspin.2017.04.010
   PubMed Web of Science ®Google Scholar
• Firinu D, Barca MP, Lorrai MM, et al. TH17 cells are increased in the peripheral blood of patients with SAPHO syndrome. Autoimmunity. 2014;47(6):389–394. doi:10.3109/08916934.2014.906582
   PubMed Web of Science ®Google Scholar
• Wendling D, Aubin F, Verhoeven F, Prati C. IL-23/Th17 targeted therapies in SAPHO syndrome. A case series. Joint Bone Spine. 2017;84(6):733–735. doi:10.1016/j.jbspin.2017.05.016
   PubMed Web of Science ®Google Scholar
• Xu D, Liu X, Lu C, et al. Reduction of peripheral natural killer cells in patients with SAPHO syndrome. Clin Exp Rheumatol. 2019;37(1):12–18.
   PubMed Web of Science ®Google Scholar
• Grosjean C, Hurtado-Nedelec M, Nicaise-Roland P, et al. Prevalence of autoantibodies in SAPHO syndrome: a single-center study of 90 patients. J Rheumatol. 2010;37(3):639–643. doi:10.3899/jrheum.090863
   PubMed Web of Science ®Google Scholar
• Zhang S, Li C, Zhang S, et al. Serum levels of proinflammatory, anti-inflammatory cytokines, and RANKL/OPG in synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome. Mod Rheumatol. 2019;29(3):523–530. doi:10.1080/14397595.2018.1469580
   PubMed Web of Science ®Google Scholar
• Daoussis D, Konstantopoulou G, Kraniotis P, Sakkas L, Liossis SN. Biologics in SAPHO syndrome: a systematic review. Semin Arthritis Rheum. 2019;48(4):618–625. doi:10.1016/j.semarthrit.2018.04.003
   PubMed Web of Science ®Google Scholar
• Olivieri I, Padula A, Ciancio G, Salvarani C, Niccoli L, Cantini F. Successful treatment of SAPHO syndrome with infliximab: report of two cases. Ann Rheum Dis. 2002;61(4):375–376.
   PubMed Web of Science ®Google Scholar
• Wagner AD, Andresen J, Jendro MC, Hulsemann JL, Zeidler H. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum. 2002;46(7):1965–1968.
   PubMed Web of Science ®Google Scholar
• Iqbal M, Kolodney MS. Acne fulminans with synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome treated with infliximab. J Am Acad Dermatol. 2005;52(5 Suppl 1):S118–120.
   PubMed Web of Science ®Google Scholar
• Deutschmann A, Mache CJ, Bodo K, Zebedin D, Ring E. Successful treatment of chronic recurrent multifocal osteomyelitis with tumor necrosis factor-alpha blockage. Pediatrics. 2005;116(5):1231–1233.
   PubMed Web of Science ®Google Scholar
• Massara A, Cavazzini PL, Trotta F. In SAPHO syndrome anti-TNF-alpha therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations. Rheumatology (Oxford). 2006;45(6):730–733.
   PubMed Web of Science ®Google Scholar
• Moll C, Hernandez MV, Canete JD, et al. Ilium osteitis as the main manifestation of the SAPHO syndrome: response to infliximab therapy and review of the literature. Semin Arthritis Rheum. 2008;37(5):299–306.
   PubMed Web of Science ®Google Scholar
• Sabugo F, Liberman C, Niedmann JP, Soto L, Cuchacovich M. Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism. Clin Rheumatol. 2008;27(4):533–535.
   PubMed Web of Science ®Google Scholar
• Fruehauf J, Cierny-Modre B, Caelen Lel S, Schwarz T, Weinke R, Aberer E. Response to infliximab in SAPHO syndrome. BMJ Case Rep. 2009;2009.
   PubMedGoogle Scholar
• Ben Abdelghani K, Dran DG, Gottenberg JE, Morel J, Sibilia J, Combe B. Tumor necrosis factor-alpha blockers in SAPHO syndrome. J Rheumatol. 2010;37(8):1699–1704.
   PubMed Web of Science ®Google Scholar
• Eleftheriou D, Gerschman T, Sebire N, Woo P, Pilkington CA, Brogan PA. Biologic therapy in refractory chronic non-bacterial osteomyelitis of childhood. Rheumatology (Oxford). 2010;49(8):1505–1512.
   PubMed Web of Science ®Google Scholar
• De Souza A, Solomon GE, Strober BE. SAPHO syndrome associated with hidradenitis suppurativa successfully treated with infliximab and methotrexate. Bull NYU Hosp Jt Dis. 2011;69(2):185–187.
   PubMedGoogle Scholar
• Burgemeister LT, Baeten DL, Tas SW. Biologics for rare inflammatory diseases: TNF blockade in the SA PHO syndrome. Neth J Med. 2012;70(10):444–449.
   PubMed Web of Science ®Google Scholar
• Hampton SL, Youssef H. Successful treatment of resistant SAPHO syndrome with anti-TNF therapy. BMJ Case Rep. 2013;2013.
   PubMedGoogle Scholar
• Anić B, Padjen I, Baresic M, Tezak S. The lobster sign in SAPHO syndrome: unusually extensive osteitis of the anterior chest wall partially responsive to infliximab. Rheumatol Int. 2014;34(2):281–282.
   PubMed Web of Science ®Google Scholar
• Li C, Wu X, Cao Y, et al. Paradoxical skin lesions induced by anti-TNF-alpha agents in SAPHO syndrome. Clin Rheumatol. 2019;38(1):53–61.
   PubMed Web of Science ®Google Scholar
• Borok S, Flusser G, Elkayam O. Clinical Images: marked inflammation in a patient with cervical vertebral SAPHO complicated by vertebral body collapse and severe kyphosis. Isr Med Assoc J. 2017;19(11):725–726.
   PubMed Web of Science ®Google Scholar
• Asano T, Furuya MY, Fujita Y, et al. Diagnostic value of ultrasonography in synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome: a case report. Medicine (Baltimore). 2018;97(41):e12725.
   PubMed Web of Science ®Google Scholar
• Vilar-Alejo J, Dehesa L, de la Rosa-del Rey P, et al. SAPHO syndrome with unusual cutaneous manifestations treated successfully with etanercept. Acta Derm Venereol. 2010;90(5):531–532.
   PubMed Web of Science ®Google Scholar
• Zhang LL, Zhao JX, Liu XY. Successful treatment of SAPHO syndrome with severe spinal disorder using entercept: a case study. Rheumatol Int. 2012;32(7):1963–1965.
   PubMed Web of Science ®Google Scholar
• Su YS, Chang CH. SAPHO syndrome associated with acne conglobata successfully treated with etanercept. J Formos Med Assoc. 2015;114(6):562–564.
   PubMed Web of Science ®Google Scholar
• Abourazzak FE, Hachimi H, Kadi N, Berrada K, Tizniti S, Harzy T. Etanercept in the treatment of SAPHO syndrome: which place? Eur J Rheumatol. 2014;1(3):125–128.
   PubMedGoogle Scholar
• Marí A, Morla A, Melero M, Schiavone R, Rodriguez J. Diffuse sclerosing osteomyelitis (DSO) of the mandible in SAPHO syndrome: a novel approach with anti-TNF therapy. Systematic review. J Craniomaxillofac Surg. 2014;42(8):1990–1996.
   PubMed Web of Science ®Google Scholar
• Sàez-Martin LC, Gomez-Castro S, Roman-Curto C, Palacios-Alvarez I, Fernandez-Lopez E. Etanercept in the treatment of SAPHO syndrome. Int J Dermatol. 2015;54(6):e206–208.
   PubMed Web of Science ®Google Scholar
• Zhang L, Gao Z. Etanercept in the treatment of refractory SAPHO syndrome. Am J Clin Exp Immunol. 2016;5(4):62–66.
   PubMedGoogle Scholar
• Zhang X, Wu X, Li C. Successful treatment of synovitis, acne, pustulosis, hyperostosis, and osteitis and paradoxical skin lesions by Tripterygium wilfordii hook f: a case report. J Int Med Res. 2020;48(9):300060520949100.
   PubMed Web of Science ®Google Scholar
• Huang H, Zhang Z, Zhao J, Hao Y, Zhou W. The effectiveness of treatments for patients with SAPHO syndrome: a follow-up study of 24 cases from a single center and review of literature. Clin Rheumatol. 2021;40(3):1131–1139.
   PubMed Web of Science ®Google Scholar
• Arias-Santiago S, Sanchez-Cano D, Callejas-Rubio JL, Fernandez-Pugnaire MA, Ortego-Centeno N. Adalimumab treatment for SAPHO syndrome. Acta Derm Venereol. 2010;90(3):301–302.
   PubMed Web of Science ®Google Scholar
• Castellví I, Bonet M, Narvaez JA, Molina-Hinojosa JC. Successful treatment of SAPHO syndrome with Adalimumab: a case report. Clin Rheumatol. 2010;29(10):1205–1207.
   PubMed Web of Science ®Google Scholar
• Henriques CC, Sousa M, Panarra A, Riso N. The dark side of SAPHO syndrome. BMJ Case Rep. 2011;2011.
   PubMedGoogle Scholar
• Hess S, Hospach T, Nossal R, Dannecker G, Magdorf K, Uhlemann F. Life-threatening disseminated tuberculosis as a complication of TNF-alpha blockade in an adolescent. Eur J Pediatr. 2011;170(10):1337–1342.
   PubMed Web of Science ®Google Scholar
• Garcovich S, Amelia R, Magarelli N, Valenza V, Amerio P. Long-term treatment of severe SAPHO syndrome with adalimumab: case report and a review of the literature. Am J Clin Dermatol. 2012;13(1):55–59.
   PubMed Web of Science ®Google Scholar
• Cotti E, Careddu R, Schirru E, et al. A case of SAPHO syndrome with endodontic implications and treatment with biologic drugs. J Endod. 2015;41(9):1565–1570.
   PubMed Web of Science ®Google Scholar
• Chou A, Schulman JM, Gross AJ, Jordan RC, Ramos DM. Gingival pustules and sterile diffuse sclerosing osteomyelitis as a feature of synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;121(5):e116–122.
   PubMed Web of Science ®Google Scholar
• Vekic DA, Woods J, Lin P, Cains GD. SAPHO syndrome associated with hidradenitis suppurativa and pyoderma gangrenosum successfully treated with adalimumab and methotrexate: a case report and review of the literature. Int J Dermatol. 2018;57(1):10–18.
   PubMed Web of Science ®Google Scholar
• Cianci F, Zoli A, Gremese E, Ferraccioli G. Clinical heterogeneity of SAPHO syndrome: challenging diagnose and treatment. Clin Rheumatol. 2017;36(9):2151–2158.
   PubMed Web of Science ®Google Scholar
• Marrani E, Belli G, Simonini G, Trapani S, Caproni M, Lionetti P. SAPHO syndrome in pediatric patients with inflammatory bowel disease treated with infliximab. Dig Liver Dis. 2018;50(11):1249–1251.
   PubMedGoogle Scholar
• Genovese G, Caorsi R, Moltrasio C, Marzano AV. Successful treatment of co-existent SAPHO syndrome and hidradenitis suppurativa with adalimumab and methotrexate. J Eur Acad Dermatol Venereol. 2019;33(Suppl 6):40–41.
   PubMed Web of Science ®Google Scholar
• Luzzati M, Simonini G, Filippeschi C, Giani T, Trapani S. SAPHO syndrome: the supposed trigger by isotretinoin, the efficacy of adalimumab and the specter of depressive disorder: a case report. Ital J Pediatr. 2020;46(1):169.
   PubMed Web of Science ®Google Scholar
• Kamata Y, Minota S. Successful treatment of a patient with SAPHO syndrome with certolizumab pegol. Rheumatol Int. 2015;35(9):1607–1608.
   PubMed Web of Science ®Google Scholar
• Liew J, Xu TH, Chu CQ. Synovitis acne pustulosis hyperostosis osteitis (SAPHO) - paradoxical reactions and different responses to tumour necrosis factor inhibitors. Rheumatology (Oxford). 2017;56(12):2239–2241.
   PubMed Web of Science ®Google Scholar
• Colina M, Pizzirani C, Khodeir M, et al. Dysregulation of P2X7 receptor-inflammasome axis in SAPHO syndrome: successful treatment with anakinra. Rheumatology (Oxford). 2010;49(7):1416–1418.
   PubMed Web of Science ®Google Scholar
• Wendling D, Prati C, Aubin F. Anakinra treatment of SAPHO syndrome: short-term results of an open study. Ann Rheum Dis. 2012;71(6):1098–1100.
   PubMed Web of Science ®Google Scholar
• Rech J, Manger B, Lang B, Schett G, Wilhelm M, Birkmann J. Adult-onset Still’s disease and chronic recurrent multifocal osteomyelitis: a hitherto undescribed manifestation of autoinflammation. Rheumatol Int. 2012;32(6):1827–1829.
   PubMed Web of Science ®Google Scholar
• Sakran W, Shalev SA, Sakran W, et al. Chronic recurrent multifocal osteomyelitis and deficiency of interleukin-1-receptor antagonist. Pediatr Infect Dis J. 2013;32(1):94.
   PubMed Web of Science ®Google Scholar
• Fujita S, Kosaka N, Mito T, Hayashi H, Morita Y. Development of aseptic subcutaneous abscess after tocilizumab therapy in a patient with SAPHO syndrome complicated by amyloid A amyloidosis. Int J Rheum Dis. 2015;18(4):476–479.
   PubMed Web of Science ®Google Scholar
• Sato H, Wada Y, Hasegawa E, et al. Adult-onset chronic recurrent multifocal osteomyelitis with high intensity of muscles detected by magnetic resonance imaging, successfully controlled with tocilizumab. Intern Med. 2017;56(17):2353–2360.
   PubMed Web of Science ®Google Scholar
• Sun XC, Liu S, Li C, et al. Failure of tocilizumab in treating two patients with refractory SAPHO syndrome: a case report. J Int Med Res. 2018;46(12):5309–5315.
   PubMed Web of Science ®Google Scholar
• Cornillier H, Kervarrec T, Tabareau-Delalande F, Mammou S, Jonville Bera AP, Machet L. Interstitial granulomatous dermatitis occurring in a patient with SAPHO syndrome one month after starting leflunomide, and subsequently disappearing with ustekinumab. Eur J Dermatol. 2016;26(6):614–615.
   PubMed Web of Science ®Google Scholar
• Firinu D, Garcia-Larsen V, Manconi PE, Del Giacco SR. SAPHO syndrome: current developments and approaches to clinical treatment. Curr Rheumatol Rep. 2016;18(6):35.
   PubMed Web of Science ®Google Scholar
• Wang L, Sun B, Li C. Clinical and radiological remission of osteoarticular and cutaneous lesions in SAPHO patients treated with secukinumab: a case series. J Rheumatol. 2021;48(6):953–955.
   PubMed Web of Science ®Google Scholar
• Sun B, Cao Y, Wang L, Wang M, Li C. Successful treatment of refractory mandibular lesions in SAPHO syndrome with secukinumab. Rheumatology (Oxford). 2021;60(1):473–474.
   PubMed Web of Science ®Google Scholar
• Adamo S, Nilsson J, Krebs A, et al. Successful treatment of SAPHO syndrome with apremilast. Br J Dermatol. 2018;179(4):959–962.
   PubMed Web of Science ®Google Scholar
• Yang Q, Zhao Y, Li C, Luo Y, Hao W, Zhang W. Case report: successful treatment of refractory SAPHO syndrome with the JAK inhibitor tofacitinib. Medicine (Baltimore). 2018;97(25):e11149.
   PubMed Web of Science ®Google Scholar
• Liu S, Li C, Tang MW, et al. Improvement of lymphangioleiomyomatosis following successful tofacitinib treatment for refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome. Chin Med J (Engl). 2019;132(19):2378–2379.
   PubMed Web of Science ®Google Scholar
• Li B, Li GW, Xue L, Chen YY. Rapid remission of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome in response to the Janus kinase inhibitor tofacitinib: a case report. World J Clin Cases. 2020;8(19):4527–4534.
   PubMed Web of Science ®Google Scholar
• Li Y, Huo J, Cao Y, et al. Efficacy of tofacitinib in synovitis, acne, pustulosis, hyperostosis and osteitis syndrome: a pilot study with clinical and MRI evaluation. Ann Rheum Dis. 2020;79(9):1255–1257.
   PubMed Web of Science ®Google Scholar
• Li C, Li Z, Cao Y, et al. Tofacitinib for the treatment of nail lesions and palmoplantar pustulosis in synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome. JAMA Dermatol. 2021;157(1):74–78.
   PubMed Web of Science ®Google Scholar
• Mateo L, Sanint J, Rodriguez Muguruza S, Martinez Morillo M, Perez Andres R, Domenech Puigcerver S. SAPHO syndrome presenting as an osteolytic lesion of the neck. Reumatol Clin. 2017;13(1):44–47.
   PubMed Web of Science ®Google Scholar
• Lee A, Scott LJ. Certolizumab pegol: a review in moderate to severe plaque psoriasis. BioDrugs. 2020;34(2):235–244.
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Narang K. Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential. Ther Adv Musculoskelet Dis. 2013;5(5):277–285.
   PubMedGoogle Scholar
• Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(1):1–26.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699.
   PubMed Web of Science ®Google Scholar
• Keating GM. Apremilast: a review in psoriasis and psoriatic arthritis. Drugs. 2017;77(4):459–472.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Mao X, Li W, et al. Tripterygium wilfordii: an inspiring resource for rheumatoid arthritis treatment. Med Res Rev. 2021;41(3):1337–1374.
   PubMed Web of Science ®Google Scholar
• Wang L, Gong L, Zhang X, et al. Tripterygium wilfordii Hook F. in the treatment of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a clinical trial. Clin Rheumatol. 2021;40(6):2427–2438.
   PubMed Web of Science ®Google Scholar
• Li C, Sun X, Cao Y, Xu W, Zhang W, Dong Z. Case report: remarkable remission of SAPHO syndrome in response to Tripterygium wilfordii hook f treatment. Medicine (Baltimore). 2017;96(47):e8903.
   PubMed Web of Science ®Google Scholar
• Gong L, Wang L, Cao Y, Li C. Rapid induction of clinical remission in SAPHO syndrome using high-dose Tripterygium glycosides: a case report. Medicine (Baltimore). 2020;99(27):e21102.
   PubMed Web of Science ®Google Scholar
• Nguyen MT, Borchers A, Selmi C, Naguwa SM, Cheema G, Gershwin ME. The SAPHO syndrome. Semin Arthritis Rheum. 2012;42(3):254–265.
   PubMed Web of Science ®Google Scholar
• Aljuhani F, Tournadre A, Tatar Z, et al. The SAPHO syndrome: a single-center study of 41 adult patients. J Rheumatol. 2015;42(2):329–334.
   PubMed Web of Science ®Google Scholar
• Galadari H, Bishop AG, Venna SS, Sultan E, Do D, Zeltser R. Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome treated with a combination of isotretinoin and pamidronate. J Am Acad Dermatol. 2009;61(1):123–125.
   PubMed Web of Science ®Google Scholar
• Soyfoo MS, Gangji V, Margaux J. Successful treatment of SAPHO syndrome with ibandronate. J Clin Rheumatol. 2010;16(5):253.
   PubMed Web of Science ®Google Scholar
• Just A, Adams S, Brinkmeier T, et al. Successful treatment of primary chronic osteomyelitis in SAPHO syndrome with bisphosphonates. J Dtsch Dermatol Ges. 2008;6(8):657–660.
   PubMed Web of Science ®Google Scholar
• Spyridonidis T, Giannakenas C, Papandrianos N, Barla P, Apostolopoulos DJ. Two cases of synovitis, acne, pustulosis, osteitis–SAPHO syndrome. Hell J Nucl Med. 2007;10(2):109–112.
   PubMed Web of Science ®Google Scholar
• Amital H, Applbaum YH, Aamar S, Daniel N, Rubinow A. SAPHO syndrome treated with pamidronate: an open-label study of 10 patients. Rheumatology (Oxford). 2004;43(5):658–661.
   PubMed Web of Science ®Google Scholar
• Courtney PA, Hosking DJ, Fairbairn KJ, Deighton CM. Treatment of SAPHO with pamidronate. Rheumatology (Oxford). 2002;41(10):1196–1198.
   PubMed Web of Science ®Google Scholar
• Susanto CR, Nanayakkara PW. The skin is the clue. Eur J Intern Med. 2003;14(8):493–494.
   PubMedGoogle Scholar
• Kim CH, Kadhim S, Julien C. Treatment of pain in SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome. PM R. 2014;6(1):92–95.
   PubMedGoogle Scholar
• Ucciferri C, Vecchiet J, Falasca K. Role of monoclonal antibody drugs in the treatment of COVID-19. World J Clin Cases. 2020;8(19):4280–4285.
   PubMed Web of Science ®Google Scholar
• LaBranche TP, Jesson MI, Radi ZA, et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum. 2012;64(11):3531–3542.
   PubMed Web of Science ®Google Scholar